Mycophenolat Mofetil Sandoz (Mycophenolate Mofetil)

Mycophenolate Mofetil, the active ingredient in Mycophenolat Mofetil Sandoz, is an antimetabolite presented as a tablet for oral use. It selectively inhibits lymphocyte proliferation and is employed to prevent organ transplant rejection and to treat autoimmune conditions such as lupus nephritis.

GNH USA supplies Mycophenolat Mofetil Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide, adhering to stringent quality standards and providing regulatory support for global distribution.

Mycophenolate Mofetil is an immunosuppressant used in conditions where inhibition of lymphocyte proliferation is required. - Organ transplant rejection: helps prevent acute and chronic rejection of transplanted organs. - Lupus nephritis: reduces renal inflammation and proteinuria in systemic lupus erythematosus affecting the kidneys. - Autoimmune diseases: controls immune activity in selected autoimmune disorders such as certain vasculitides.

Mycophenolate Mofetil may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Gastrointestinal upset: nausea, vomiting, diarrhea. - Hematologic changes: leukopenia, anemia, thrombocytopenia. - Infections: increased susceptibility to bacterial, viral, and fungal infections. - Headache and dizziness. - Elevated liver enzymes.

Serious or Rare Side Effects: - Severe infection or sepsis. - Progressive multifocal leukoencephalopathy (PML). - Life‑threatening hypersensitivity reactions. - Malignancies such as lymphomas. - Renal dysfunction or acute kidney injury.

Before initiating therapy, clinicians should assess patient risk factors and monitor laboratory parameters regularly. - Pregnancy: contraindicated (Category X) due to fetal toxicity. - Infection risk: screen for latent infections and monitor for new infections. - Hematologic monitoring: perform regular complete blood counts. - Renal function: adjust dose in renal impairment and monitor creatinine. - Drug interactions: review concomitant medications for potential interactions. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original container.

Mycophenolate Mofetil can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Live vaccines: concurrent use may cause severe infection. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce drug exposure. - Antacids containing aluminum or magnesium: can decrease absorption of mycophenolic acid.

Moderate Interactions (Monitor Closely): - Azathioprine: additive bone‑marrow suppression. - Warfarin: may increase INR and bleeding risk. - ACE inhibitors or ARBs: monitor renal function and potassium levels.